Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.31, read 2026-11-02
Ethical does not pass the values gate
Price8.47 USD
Fair value12.00
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-09-21Read Markdown9.16-7.5% to today ✓Accumulation gives way to Markdown after a 23% slide in 4 weeks
2026-08-21Read Accumulation11.85-28.5% to today Distribution gives way to Accumulation after a 27% slide in 7 weeks
2026-07-02Read Distribution16.31-48.1% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Amprius Technologies, Inc. holds its Markdown at $8.47. Consolidating, no directional conviction, held for 7 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 7 days
Price at the screen
$8.47
Valuation
N/A trailing · 84.70 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.38
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.41%
Below 33%
Interest-bearing debt is just 25.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
72.79%
Below 49%
Money owed to the company is 72.8% of assets, above the 49% limit.
Fail
Revenue purity
3.65%
Below 5%
Only 3.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Amprius Technologies,'s business is fine, but its receivables are about 73% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AMPX's ethical verdict changes
Today AMPX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 29% discount to our $12.00 fair value, 125.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 29.4% discount to the base estimate.
Where our models see it going: fair-value estimate $12.00, with a range of $12.00 to $13.80, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
High flying battery hopes meet eye watering valuation
Picture a startup selling batteries that could one day power electric planes. Revenue is exploding at 153 percent, yet the firm still loses 44 percent on every pound of sales and posts negative 44 percent return on equity. At 169 times forward earnings the market is paying for perfection that has not arrived, and the absence of any identifiable moat leaves little protection if execution slips.
We pass because the modest 14 percent margin of safety to our fair value does not compensate for the stretched multiple or the unknown durability of the silicon anode technology. Strong buy ratings from nine analysts and a 22 dollar median target reflect enthusiasm, not evidence that losses will turn to durable profits soon enough to justify the price.
Risk sits mainly in execution and dilution for a business that has yet to prove it can scale without burning cash. The ethical screen is clean, but that alone does not create an investment case. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMPX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$8.47-4.1%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$8.83+2.8%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$8.59+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$8.59+3.4%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
2026-10-26Markdown$8.31-1.1%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
2026-10-19Markdown$8.40-11.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
2026-10-12Markdown$9.44-1.8%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
2026-10-02Markdown$9.61+4.9%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
2026-09-21Markdown · changed$9.16-22.7%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 22.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 16.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
